Novel Approach to
Treating Cancers and
Neurological Diseases
Pannex Therapeutics is focused on developing first-in-class Pannexin 1 channel (Panx1)
blockers to deliver safer, more effective treatments for life-threatening cancers, such as
triple-negative breast cancer (TNBC), and severe neurological diseases like chronic pain.
Discover our science
Pannexin 1
Blocking Panx1 channels reduces harmful cell signaling, e ectively disrupting disease related pathways and therefore improves disease progression and outcomes.
ScienceOur team
David Bravo PhD
Chief Executive Officer &
Co-founder
Pannexin 1 research leader with more than a decade of success in drug discovery and innovation
Thomas Gerlach PhD
Chief Strategic Officer &
Co-founder
Biochemist with over 30 years of experience in global drug development, commercialization and venture capital
Gerhard Gross PhD
Chief Scientific Officer &
Co-founder
Chemist with 30 years of experience in drug discovery and development - 14 FDA - approved drugs